Patents Assigned to The Public Health Research Institute of the City of New
York
-
Patent number: 6103463Abstract: A method of sorting mixtures of nucleic acid strands comprising hybridizing the strands to an array of immobilized oligonucleotides, each of which includes a constant segment adjacent to a variable segment. The constant segment of the immobilized oligonucleotides can be made complementary to the ends of strands obtained by digesting a double-stranded nucleic acid with a restriction enzyme and restoring the restriction sites, thereby permitting the sorting of strands according to their variable sequences adjacent to their constant terminal restored restriction sites.Type: GrantFiled: May 23, 1994Date of Patent: August 15, 2000Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Alexander B. Chetverin, Fred Russell Kramer
-
Patent number: 6103476Abstract: Unimolecular and bimolecular hybridization probes for the detection of nucleic acid target sequences comprise a target complement sequence, an affinity pair holding the probe in a closed conformation in the absence of target sequence, and either a label pair that interacts when the probe is in the closed conformation or, for certain unimolecular probes, a non-interactive label. Hybridization of the target and target complement sequences shifts the probe to an open conformation. The shift is detectable due to reduced interaction of the label pair or by detecting a signal from a non-interactive label. Certain unimolecular probes can discriminate between target and non-target sequences differing by as little as one nucleotide. Also, universal stems and kits useful for constructing said probes. Also, assays utilizing said probes and kits for performing such assays.Type: GrantFiled: March 15, 1999Date of Patent: August 15, 2000Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Sanjay Tyagi, Fred R. Kramer, Paul M. Lizardi
-
Patent number: 6087163Abstract: Two genes for proteins of M. tuberculosis have been sequenced. The DNAs and their encoded polypeptides can be used for immunoassays and vaccines. Cocktails of at least three purified recombinant antigens, and cocktails of at least three DNAs encoding them can be used for improved assays and vaccines for bacterial pathogens and parasites.Type: GrantFiled: February 6, 1997Date of Patent: July 11, 2000Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Maria L. Gennaro, Konstantin P. Lyashchenko, Claudia M.A. Manca
-
Patent number: 5952474Abstract: Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.Type: GrantFiled: July 1, 1997Date of Patent: September 14, 1999Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Samuel Kayman, Abraham Pinter
-
Patent number: 5925517Abstract: Unimolecular and bimolecular hybridization probes for the detection of nucleic acid target sequences comprise a target complement sequence, an affinity pair holding the probe in a closed conformation in the absence of target sequence, and either a label pair that interacts when the probe is in the closed conformation or, for certain unimolecular probes, a non-interactive label. Hybridization of the target and target complement sequences shifts the probe to an open conformation. The shift is detectable due to reduced interaction of the label pair or by detecting a signal from a non-interactive label. Certain unimolecular probes can discriminate between target and non-target sequences differing by as little as one nucleotide. Also, universal stems and kits useful for constructing said probes. Also, assays utilizing said probes and kits for performing such assays.Type: GrantFiled: May 12, 1995Date of Patent: July 20, 1999Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Sanjay Tyagi, Fred R. Kramer, Paul M. Lizardi
-
Patent number: 5922325Abstract: A synergistic combination of antibodies specific for HIV envelope glycoprotein gp120 is described. One of the antibodies specific for the V3 loop and the other is specific for the CD-4 binding site of gp120.Type: GrantFiled: May 22, 1995Date of Patent: July 13, 1999Assignee: Public Health Research Institute of the City of New York, Inc.Inventors: Shermaine A. Tilley, Abraham Pinter
-
Patent number: 5759773Abstract: Nucleic acid sandwich hybridization assays are provided that incorporate one or a combination of background reduction steps. Those steps include use of a separate capture probe and separation from immobilized capture probes by cleavage and isolation. A very sensitive assay for RNA targets includes both of those steps, plus RNA binary probes, an RNA-directed RNA ligase and amplification by an RNA-directed RNA polymerase. Kits of reagents for performing assays according to this invention are also provided.Type: GrantFiled: February 24, 1995Date of Patent: June 2, 1998Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Sanjay Tyagi, Fred R. Kramer, Paul M. Lizardi, Ulf D. Landegren, Herman J. Blok
-
Patent number: 5652107Abstract: There are provided nucleic acid hybridization assays for RNA targets using RNA binary probes and a ribozyme ligase that is a stringent RNA-directed RNA ligase. Preferred assays include exponential amplification for signal generation. Tetrahymena ribozyme ligase is a preferred ligase for use in this invention. It may be tethered to hold it close to the ligation junction. One assay according to this invention is a "tethered ligase chain reaction." Also provided are kits for performing assays according to the invention.Type: GrantFiled: July 15, 1996Date of Patent: July 29, 1997Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Paul M. Lizardi, Sanjay Tyagi, Ulf D. Landegren, Fred R. Kramer, Jack W. Szostak
-
Patent number: 5643756Abstract: Novel expression vectors are provided for expressing a fusion glycoprotein. The fusion glycoprotein contains the N-terminal globular domain of a retroviral env surface protein linked to a selected glycopeptide. Truncation glycoproteins as well as insertion glycoproteins are expressed using the vectors.Type: GrantFiled: August 20, 1993Date of Patent: July 1, 1997Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Samuel Kayman, Abraham Pinter
-
Patent number: 5616459Abstract: Mutant ribozymes are screened by culturing cells whose survival is dependant upon cleavage of RNA by a ribozyme, which cleavage causes the cells to survive in the presence of an agent which otherwise would kill the cells, and selecting cells which survive.Type: GrantFiled: August 18, 1992Date of Patent: April 1, 1997Assignee: The Public Health Research Institute of the City of New York, Inc.Inventors: Fred R. Kramer, David Dubnau, Karl A. Drlica, Abraham Pinter
-
Patent number: 5312728Abstract: A probe for the detection of a nucleic acid target sequence containing a molecular switch comprising three essential elements: a probe sequence of 20-60 nucleotides surrounded by switch sequences of 10-40 nucleotides which are complementary to each other, wherein the state of the switch is useful for selectively generating a detectable signal if the probe is hybridized to a target; also, assays and kits utilizing such probes.Type: GrantFiled: May 4, 1992Date of Patent: May 17, 1994Assignees: Public Health Research Institute of the City of New York, Inc., The Salk Institute for Biological StudiesInventors: Paul M. Lizardi, Fred R. Kramer, Sanjay Tyagi, Cesar E. Guerra, Hilda M. L. Buyoli, Barbara C. Chu, Gerald F. Joyce, Leslie E. Orgel
-
Patent number: 5135910Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.Type: GrantFiled: February 11, 1991Date of Patent: August 4, 1992Assignee: The Public Health Research Institute of the City of New YorkInventors: Peter Blackburn, June Polak, Sara-Ann Gusik, Stephen D. Rubino
-
Patent number: 4980163Abstract: Broad range bacteriocin compositions are provided. The compositions can be dissolved or suspended in a suitable solvent or matrix and are more active towards a broader range of bacteria than are any of the component parts. The dissolved or suspended compositions constitute enhanced broad range bactericides. The compositions include lysostaphin and a lanthionine containing peptide bacteriocin; lysostaphin, a lanthionine containing peptide bacteriocin and a chelating agent; and lysostaphin, a lanthionine containing peptide, a chelating agent and a surfactant. Each component is present in the enhanced broad range bactericide in sufficient amount such that the bactericide is more effective against staphylococci than is lysostaphin alone and is more effective at treating and preventing a broad range of microbial infections. Methods of treating bacterial infections using said compositions and bactericides are provided.Type: GrantFiled: March 1, 1989Date of Patent: December 25, 1990Assignee: Public Health Research Institute of the City of New YorkInventors: Peter Blackburn, Sara-Ann Gusik, June Polak, Stephen D. Rubino
-
Patent number: 4931390Abstract: The present invention provides recombinant plasmids which is transformant microbial hosts express lysostaphin, a bacteriocin that kills most known staphylococcal species. The invention also provides lysostaphin, substantially free from non-lysostaphin contaminants. Recombinant plasmids, pRG5, pJP1, pDF8 and pRP1, were derived by inserting a 1.5 kilobase segment of DNA coding for lysostaphin into the cloning vectors, pUC8, pBC16, pBD64 and pSPV1, respectively. E. coli strain JM105 transformed by pRG5 and members of Bacillus species, including B. subtilis and B. sphaericus transformed by pJP1, pDF8 and pRP1 produce lysostaphin which is immunologically and electrophoretically indistinguishable from that produced by S. simulans, the natural source. Furthermore, B. sphaericus strain 00/pJP1 transformants produce five times the amount of lysostaphin as S. simulans. The invention also provides the 1.5 kbp DNA fragment coding for lysostaphin.Type: GrantFiled: April 10, 1987Date of Patent: June 5, 1990Assignee: Public Health Research Institute of the City of New York, Inc.Inventor: Paul A. Recsei
-
Patent number: 4663280Abstract: The present invention relates to an expression and secretion vector which comprises the signal and promoter sequence of the Bacillus cereus (herein "B. cereus") gene which codes for penicillinase and to the construction of vectors and the use of the vectors in the expression and secretion of one or more exogenous polypeptides in microorganisms for example, B. subtilis.Type: GrantFiled: December 2, 1983Date of Patent: May 5, 1987Assignee: Public Health Research Institute of the City of New YorkInventor: Alan Sloma